1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Bacterial Pneumonia - Pipeline Review, H1 2016

Bacterial Pneumonia - Pipeline Review, H1 2016

  • June 2016
  • -
  • Global Markets Direct
  • -
  • 200 pages

Bacterial Pneumonia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Bacterial Pneumonia - Pipeline Review, H1 2016’, provides an overview of the Bacterial Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia
- The report reviews pipeline therapeutics for Bacterial Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bacterial Pneumonia therapeutics and enlists all their major and minor projects
- The report assesses Bacterial Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bacterial Pneumonia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bacterial Pneumonia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bacterial Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Bacterial Pneumonia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2

Introduction 8
Global Markets Direct Report Coverage 8
Bacterial Pneumonia Overview 9
Therapeutics Development 10
Pipeline Products for Bacterial Pneumonia - Overview 10
Pipeline Products for Bacterial Pneumonia - Comparative Analysis 11
Bacterial Pneumonia - Therapeutics under Development by Companies 12
Bacterial Pneumonia - Therapeutics under Investigation by Universities/Institutes 16
Bacterial Pneumonia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Bacterial Pneumonia - Products under Development by Companies 21
Bacterial Pneumonia - Products under Investigation by Universities/Institutes 25
Bacterial Pneumonia - Companies Involved in Therapeutics Development 26
Abera Bioscience AB 26
Actelion Ltd 27
Alvogen Korea Co., Ltd. 28
Aridis Pharmaceuticals LLC 29
Arsanis Biosciences GmbH 30
AstraZeneca Plc 31
Beijing Minhai Biotechnology Co., Ltd 32
ContraFect Corporation 33
Daiichi Sankyo Company, Limited 34
Double Bond Pharmaceutical International AB 35
Emergent BioSolutions Inc. 36
Eurocine Vaccines AB 37
FluGen, Inc. 38
GlaxoSmithKline Plc 39
Humabs BioMed SA 40
ImmunoBiology Limited 41
Indian Immunologicals Limited 42
Integrated BioTherapeutics, Inc. 43
Kyorin Pharmaceutical Co., Ltd. 44
Lascco SA 45
LG Life Science LTD. 46
Liquidia Technologies, Inc. 47
MedImmune, LLC 48
Merck and Co., Inc. 49
Mucosis B.V. 50
Noxxon Pharma AG 51
Panacea Biotec Limited 52
Prometheon Pharma, LLC 53
Sanofi Pasteur SA 54
Serum Institute of India Limited 55
SK Chemicals Co., Ltd. 56
Sumitomo Dainippon Pharma Co., Ltd. 57
Valneva SE 58
Vaxxilon AG 59
Virometix AG 60
Walvax Biotechnology Co., Ltd. 61
Wellstat Vaccines, LLC 62
Wockhardt Limited 63
Bacterial Pneumonia - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Target 66
Assessment by Mechanism of Action 68
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
(cilastatin sodium + imipenem + relebactam) - Drug Profile 74
(Streptococcal pneumonia + typhoid) vaccine - Drug Profile 75
Ab-01 - Drug Profile 76
ACT-292706 - Drug Profile 77
ACT-387042 - Drug Profile 78
Aerucin - Drug Profile 79
ASN-400 - Drug Profile 81
AT-62aa - Drug Profile 82
AZ-6142 - Drug Profile 84
CAL-02 - Drug Profile 85
CB-027 - Drug Profile 86
cefepime + zidebactam - Drug Profile 87
CF-301 - Drug Profile 88
CF-302 - Drug Profile 91
CF-303 - Drug Profile 92
CF-309 - Drug Profile 93
DEF-201 - Drug Profile 94
doxycycline - Drug Profile 96
EV-035 - Drug Profile 97
Fab-001 - Drug Profile 99
GSK-2189242A - Drug Profile 100
KRPAM-1977X - Drug Profile 102
KRPAM-1977Y - Drug Profile 104
LBVE - Drug Profile 105
LCB-010371 - Drug Profile 106
MEDI-3902 - Drug Profile 107
Monoclonal Antibodies for Pneumococcus Infections - Drug Profile 108
Monoclonal Antibodies to Inhibit ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders - Drug Profile 109
Monoclonal Antibody for Staphylococcus Aureus Infections - Drug Profile 110
Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Neurodegenerative Diseases - Drug Profile 111
NBP-606 - Drug Profile 112
NOXD-21 - Drug Profile 113
Nucovac - Drug Profile 114
panobacumab - Drug Profile 115
PneuGEM - Drug Profile 117
pneumococcal (13-valent) vaccine - Drug Profile 118
pneumococcal (13-valent) vaccine - Drug Profile 119
pneumococcal (13-valent) vaccine - Drug Profile 120
pneumococcal (23-valent) vaccine - Drug Profile 121
pneumococcal (23-valent) vaccine - Drug Profile 122
pneumococcal [serotype 4, 6A] vaccine - Drug Profile 123
pneumococcal [strain TIGR4] vaccine - Drug Profile 124
pneumococcal vaccine - Drug Profile 125
pneumococcal vaccine - Drug Profile 126
pneumococcal vaccine - Drug Profile 127
pneumococcal vaccine - Drug Profile 128
pneumococcal vaccine - Drug Profile 129
pneumococcal vaccine - Drug Profile 130
pneumococcal vaccine - Drug Profile 131
pneumococcal vaccine - Drug Profile 133
pneumococcal vaccine - Drug Profile 134
PneumoMab - Drug Profile 135
pneumonia vaccine - Drug Profile 136
pneumonia vaccine - Drug Profile 137
pneumonia vaccine - Drug Profile 138
PnuBioVax - Drug Profile 139
PPV-23 - Drug Profile 140
R-10001 - Drug Profile 141
Recombinant Enzyme for Pseudomonas Aeruginosa Pneumonia - Drug Profile 142
SIILPCV-10 - Drug Profile 143
SM-295291 - Drug Profile 144
SM-369926 - Drug Profile 145
Small Molecule for Respiratory Tract Infections - Drug Profile 146
Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile 147
Small Molecules for Chlamydophila Infections - Drug Profile 148
Small Molecules for Streptococcus Pneumoniae Infections - Drug Profile 149
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 150
SRT-3025 - Drug Profile 151
Staphylococcus aureus (multivalent) vaccine - Drug Profile 153
streptococcal pneumonia vaccine - Drug Profile 154
Streptococcal pneumonia vaccine - Drug Profile 155
Streptococcal pneumonia vaccine - Drug Profile 156
Streptococcal pneumonia vaccine 3 - Drug Profile 157
Streptococcus pneumonia (whole-cell) vaccine - Drug Profile 158
Streptococcus pneumonia vaccine - Drug Profile 160
Streptococcus pneumonia vaccine - Drug Profile 161
Synthetic Peptides for Bacterial Infections - Drug Profile 162
tedizolid phosphate - Drug Profile 163
V-114 - Drug Profile 170
VMT-1 - Drug Profile 171
WCK-2349 - Drug Profile 172
WCK-4873 - Drug Profile 174
WCK-771 - Drug Profile 175
Bacterial Pneumonia - Dormant Projects 176
Bacterial Pneumonia - Discontinued Products 182
Bacterial Pneumonia - Product Development Milestones 183
Featured News and Press Releases 183
Appendix 193
Methodology 193
Coverage 193
Secondary Research 193
Primary Research 193
Expert Panel Validation 193
Contact Us 193
Disclaimer 194

List of Tables
Number of Products under Development for Bacterial Pneumonia, H1 2016 16
Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H1 2016 17
Number of Products under Development by Companies, H1 2016 19
Number of Products under Development by Companies, H1 2016 (Contd..1) 20
Number of Products under Development by Companies, H1 2016 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H1 2016 22
Comparative Analysis by Late Stage Development, H1 2016 23
Comparative Analysis by Clinical Stage Development, H1 2016 24
Comparative Analysis by Early Stage Development, H1 2016 25
Comparative Analysis by Unknown Stage Development, H1 2016 26
Products under Development by Companies, H1 2016 27
Products under Development by Companies, H1 2016 (Contd..1) 28
Products under Development by Companies, H1 2016 (Contd..2) 29
Products under Development by Companies, H1 2016 (Contd..3) 30
Products under Investigation by Universities/Institutes, H1 2016 31
Bacterial Pneumonia - Pipeline by Abera Bioscience AB, H1 2016 32
Bacterial Pneumonia - Pipeline by Actelion Ltd, H1 2016 33
Bacterial Pneumonia - Pipeline by Alvogen Korea Co., Ltd., H1 2016 34
Bacterial Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 35
Bacterial Pneumonia - Pipeline by Arsanis Biosciences GmbH, H1 2016 36
Bacterial Pneumonia - Pipeline by AstraZeneca Plc, H1 2016 37
Bacterial Pneumonia - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 38
Bacterial Pneumonia - Pipeline by ContraFect Corporation, H1 2016 39
Bacterial Pneumonia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 40
Bacterial Pneumonia - Pipeline by Double Bond Pharmaceutical International AB, H1 2016 41
Bacterial Pneumonia - Pipeline by Emergent BioSolutions Inc., H1 2016 42
Bacterial Pneumonia - Pipeline by Eurocine Vaccines AB, H1 2016 43
Bacterial Pneumonia - Pipeline by FluGen, Inc., H1 2016 44
Bacterial Pneumonia - Pipeline by GlaxoSmithKline Plc, H1 2016 45
Bacterial Pneumonia - Pipeline by Humabs BioMed SA, H1 2016 46
Bacterial Pneumonia - Pipeline by ImmunoBiology Limited, H1 2016 47
Bacterial Pneumonia - Pipeline by Indian Immunologicals Limited, H1 2016 48
Bacterial Pneumonia - Pipeline by Integrated BioTherapeutics, Inc., H1 2016 49
Bacterial Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 50
Bacterial Pneumonia - Pipeline by Lascco SA, H1 2016 51
Bacterial Pneumonia - Pipeline by LG Life Science LTD., H1 2016 52
Bacterial Pneumonia - Pipeline by Liquidia Technologies, Inc., H1 2016 53
Bacterial Pneumonia - Pipeline by MedImmune, LLC, H1 2016 54
Bacterial Pneumonia - Pipeline by Merck and Co., Inc., H1 2016 55
Bacterial Pneumonia - Pipeline by Mucosis B.V., H1 2016 56
Bacterial Pneumonia - Pipeline by Noxxon Pharma AG, H1 2016 57
Bacterial Pneumonia - Pipeline by Panacea Biotec Limited, H1 2016 58
Bacterial Pneumonia - Pipeline by Prometheon Pharma, LLC, H1 2016 59
Bacterial Pneumonia - Pipeline by Sanofi Pasteur SA, H1 2016 60
Bacterial Pneumonia - Pipeline by Serum Institute of India Limited, H1 2016 61
Bacterial Pneumonia - Pipeline by SK Chemicals Co., Ltd., H1 2016 62
Bacterial Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 63
Bacterial Pneumonia - Pipeline by Valneva SE, H1 2016 64
Bacterial Pneumonia - Pipeline by Vaxxilon AG, H1 2016 65
Bacterial Pneumonia - Pipeline by Virometix AG, H1 2016 66
Bacterial Pneumonia - Pipeline by Walvax Biotechnology Co., Ltd., H1 2016 67
Bacterial Pneumonia - Pipeline by Wellstat Vaccines, LLC, H1 2016 68
Bacterial Pneumonia - Pipeline by Wockhardt Limited, H1 2016 69
Assessment by Monotherapy Products, H1 2016 70
Assessment by Combination Products, H1 2016 71
Number of Products by Stage and Target, H1 2016 73
Number of Products by Stage and Mechanism of Action, H1 2016 75
Number of Products by Stage and Route of Administration, H1 2016 77
Number of Products by Stage and Molecule Type, H1 2016 79
Bacterial Pneumonia - Dormant Projects, H1 2016 182
Bacterial Pneumonia - Dormant Projects (Contd..1), H1 2016 183
Bacterial Pneumonia - Dormant Projects (Contd..2), H1 2016 184
Bacterial Pneumonia - Dormant Projects (Contd..3), H1 2016 185
Bacterial Pneumonia - Dormant Projects (Contd..4), H1 2016 186
Bacterial Pneumonia - Dormant Projects (Contd..5), H1 2016 187
Bacterial Pneumonia - Discontinued Products, H1 2016 188

List of Figures
Number of Products under Development for Bacterial Pneumonia, H1 2016 16
Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Number of Products under Investigation by Universities/Institutes, H1 2016 22
Comparative Analysis by Late Stage Development, H1 2016 23
Comparative Analysis by Clinical Stage Development, H1 2016 24
Comparative Analysis by Early Stage Products, H1 2016 25
Assessment by Monotherapy Products, H1 2016 70
Assessment by Combination Products, H1 2016 71
Number of Products by Top 10 Targets, H1 2016 72
Number of Products by Stage and Top 10 Targets, H1 2016 72
Number of Products by Top 10 Mechanism of Actions, H1 2016 74
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 74
Number of Products by Routes of Administration, H1 2016 76
Number of Products by Stage and Routes of Administration, H1 2016 76
Number of Products by Molecule Types, H1 2016 78
Number of Products by Stage and Molecule Types, H1 2016 78

Companies Mentioned
Abera Bioscience AB
Actelion Ltd
Alvogen Korea Co., Ltd.
Aridis Pharmaceuticals LLC
Arsanis Biosciences GmbH
AstraZeneca Plc
Beijing Minhai Biotechnology Co., Ltd
ContraFect Corporation
Daiichi Sankyo Company, Limited
Double Bond Pharmaceutical International AB
Emergent BioSolutions Inc.
Eurocine Vaccines AB
FluGen, Inc.
GlaxoSmithKline Plc
Humabs BioMed SA
ImmunoBiology Limited
Indian Immunologicals Limited
Integrated BioTherapeutics, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lascco SA
LG Life Science LTD.
Liquidia Technologies, Inc.
MedImmune, LLC
Merck and Co., Inc.
Mucosis B.V.
Noxxon Pharma AG
Panacea Biotec Limited
Prometheon Pharma, LLC
Sanofi Pasteur SA
Serum Institute of India Limited
SK Chemicals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Valneva SE
Vaxxilon AG
Virometix AG
Walvax Biotechnology Co., Ltd.
Wellstat Vaccines, LLC
Wockhardt Limited

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.